EUVIMED · CrossrefZeitschrift
JCO Precision Oncology
ISSN 2473-4284 · American Society of Clinical Oncology (ASCO)
Neueste Artikel
Cancer Risks Associated With Germline BARD1 Pathogenic/Likely Pathogenic Variants: A Multicenter Study of 445 Families
Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non–Muscle-Invasive Bladder Cancer
Osimertinib Toxicity Prompting Lazertinib Monotherapy: A Case Series
Longitudinal Pancreatic Imaging Findings in BRCA1 , BRCA2 , ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study
Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk
Assessment of the 2022 Constitutional Mismatch Repair Deficiency Syndrome Diagnostic Criteria Using the International Replication Repair Deficiency Consortium
Erratum: Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers
Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials
Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort
Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2 -Mutant Non–Small Cell Lung Cancer
Germline Whole-Genome Sequencing in Early-Onset Pediatric Solid Tumors Implicates Novel Risk Factors
Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A DPYD Variant Allele
Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive Gastric Cancer
Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms
Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
Clinicogenomic Landscape and Function of PIK3CA , AKT1 , and PTEN Mutations in Breast Cancer
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience
Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non–Small Cell Lung Cancer
Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices
Evaluating Tumor Burden as a Predictive Biomarker for Epidermal Growth Factor Receptor Targeted Kinase Inhibitor Therapy in Advanced Non–Small Cell Lung Cancer
Impact of Germline BRCA Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis
Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non–Small Cell Lung Cancer
Foundation Model Based on Routine Magnetic Resonance Imaging for Brain Tumor Molecular Profiling and Progression Prediction
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation
HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing–Based Assays With Immunohistochemistry
Oncologic Outcomes by Pathogenic BRCA Mutation Status in Young Luminal Breast Cancer: A Propensity-Matched Cohort
Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry
EUVIMED